Kymera Therapeutics, Inc.
A clinical-stage biopharma developing targeted protein degradation medicines.
KYMR | US
Overview
Corporate Details
- ISIN(s):
- US5015751044
- LEI:
- Country:
- United States of America
- Address:
- 500 NORTH BEACON STREET, 4TH FLOOR, 2472 WATERTOWN
- Website:
- https://www.kymeratx.com/
Description
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the field of targeted protein degradation (TPD) to develop novel small molecule medicines. The company's proprietary drug discovery engine, Pegasus™, enables the creation of first-in-class therapeutics designed to selectively degrade disease-causing proteins, thereby addressing the root cause of illness. Kymera's pipeline is focused on developing oral medicines for diseases with high unmet medical needs, particularly in the areas of immunology, inflammation, and oncology. The company aims to redefine treatment paradigms by targeting proteins that have been previously considered undruggable.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-04 13:15 |
10-Q - Kymera Therapeutics, Inc. (0001815442) (Filer)
|
English | 2.2 MB | ||
| 2025-11-04 13:10 |
8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
|
English | 225.9 KB |
Automate Your Workflow. Get a real-time feed of all Kymera Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kymera Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kymera Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
